Essential Drugs

Total Page:16

File Type:pdf, Size:1020Kb

Essential Drugs WHO Drug Information Vol. 7, No. 2, 1993 Essential Drugs Guidelines for antimicrobial countries if the resistance of important bacterial pathogens is to be monitored. In response to this susceptibility testing need, the WHONET (2, 3) programme was (intermediate laboratories) developed by the WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. lt is now operating in some 100 hospitals, mostly in the Introduction United States, and it is expanding in South America and the western Pacific region. The system will not Although many communicable diseases have been be fully effective, however, until every country has a effectively contained, bacterial infections remain a national reference laboratory that is actively major cause of morbidity and mortality particularly reporting to this network. in developing countries. lt has been stressed repeatedly that the increas­ The concept of "reserve antimicrobials" was ing prevalence of strains of common pathogenic introduced to WHO's Model List of Essential Drugs bac-teria resistant to widely-available, relatively­ in 1989 (4). This resulted from increasing concern cheap antimicrobials such as those included in about the emergence of important pathogens that WHO's Model List of Essential Drugs (1) is have developed resistance to all "essential" dangerously eroding their effectiveness not only for antimicrobials. A reserve antimicrobial was defined the treatment of individual patients but also for the as "an antimicrobial which is useful for a wide range community at large. of infections but, because of the need to reduce the risk of development of resistance and because of Whenever one such drug or class of drugs is its relatively high cost, it would be inappropriate to used excessively, genetic changes favouring the recommend its unrestricted use". This concept emer-gence of antimicrobial-resistant bacteria becomes tangible, however, only when means exist tend to supervene. Although this can occur after of demonstrating prevailing sensitivity patterns. This only a single exposure in an individual patient, it implies a need for precise laboratory investigation. usually emerges after a sustained period of use. Without these facilities seriously-ill patients are Resistance is generally stable and passed on for endangered. several generations of bacteria. The spread of anti­ microbial-resistant clones of bacteria within a host If antimicrobial resistance is to be controlled, sev­ population or environment is also important. This is eral independent measures need to be undertaken: most noticeable in hospitals where certain resistant organisms can become endemic and may infect 1. Routine surveillance of antimicrobial-resistant many patients. The danger is intensified by poor bacteria using standardized, predictive test hygienic practices in the hospital and/or lack of methods must be introduced in hospital and adequate training in control and containment of community settings. nosocomial and other infections. The spread of resistant bacteria within the community is of even 2. Antimicrobial prescribing guidelines must be greater importance. This seriously compromises developed that will assure effective treatment and presumptive initial therapy of common bacterial not encourage the emergence and spread of infections and requires revision of routine anti­ antimicrobial-resistant bacteria. microbial strategies. 3. Comprehensive national programmes must be The need for more systematic and coordinated implemented that respect standards of good international approaches to laboratory monitoring of laboratory practice, with the objective of assuring antimicrobial sensitivity has become important and quality and availability of antimicrobials. urgent. Microbiological laboratories including national reference laboratories need to be 4. Adequate training of technical personnel must be established in developing as well as developed assured. 68 WHO Drug lnfonnation Vol. 7, No. 2, 1993 Essential Drugs 5. Systems must be developed within the context of 1. Community-acquired infections WHONET whereby each country can collate and disseminate information on antimicrobial resistance These infections are caused by organisms highly to hospitals and health workers. prevalent in the community. Some can be treated on an outpatient basis and others are severe The following guidelines concern routine surveil­ enough to require hospital admission for diagnosis lance of antimicrobial-resistant bacteria using tests and therapy. which can be undertaken in intermediate level laboratories. Causative Drugs used as markers Susceptibility testing organisms of antimicrobial resistance Since the majority of infections which arise in man are not investigated by microbiological methods, Staphylococcus aureus benzylpenicillin, oxacillin antimicrobial treatment is usually administered on erythromycin, gentamicin the basis of a presumptive etiological diagnosis determined by the clinical history and findings. Streptococcus benzylpenicillin as predicted Microbiological investigations are carried out where pneumoniae by the oxacillin disc test the etiology is uncertain, in severe infections when erythromycin patients fail to respond to empiric therapy or chloramphenicol, sulfamethoxazole develop a new infection during the course of trimethoprim therapy, or for public health purposes. Additionally, in vitro susceptibility tests are performed when an Streptococcus (benzylpenicillin)2 organism is known to have unpredictable sensitivity. pyogenes erythromycin Susceptibility tests are carried out on anti microbials Haemophilus ampicillin, chloramphenicol to which the organism is normally susceptible in influenzae sulfamethoxazole, trimethoprim order to determine whether resistance has by estimating beta­ emerged. Demonstration of a prevalence of lactamase production resistant strains could influence recommendations for presumptive antimicrobial therapy. Neisseria benzylpenicillin, tetracycline 1 1 2 gonorrhoeae (ciprofloxacin , ceftriaxone ) Clinically and epidemiologically by estimating beta­ important bacteria and essential lactamase production antimicrobials for susceptibility testing Escherichia coli ampicillin, sulfamethoxazole (UTI) trimethoprim, nitrofurantoin General principles nalidixic acid, sulfonamide (gentamicin)>2 i) The antimicrobial substances listed in these (fluoroquinolone)2- (cefalosporin)32 guidelines are commonly used in presumptive therapy. This list is illustrative rather than Salmonella typhi and ampicillin comprehensive; other drugs may be important in other invasive chloramphenicol various countries or regions. Salmonella sulfamethoxazole, trimethoprim 2 2 ii) Some of the drugs listed are index compounds (fluoroquinolone) , (cefotaxime) representative of a defined group of drugs, e.g.; oxacillin resistance in staphylococci indicates Shigella spp. ampicillin, sulfamethoxazole resistance to other beta-lactams. trimethoprim, tetracycline 2 (chloramphenicol) , nalidixic acid' iii) The most important types of resistance are easy (fluoroquinolone )2 to detect in rapidly-growing organisms. In contrast, detection of resistance in fastidious and anaerobic Vibrio cholerae tetracyclines, sulfamethoxazole bacteria requires a high degree of technical trimethoprim, nitrofurantoin 2 expertise. In such circumstances, testing should be (erythromycin) , (chloramphenicol)2 carried out in central reference laboratories, wherever possible. 69 Essential Drugs WHO Drug Information Vol. 7, No. 2, 1993 2. Hospital-acquired infections 3. Central reference laboratories usually located in the capital city or in a university hospital. These infections arise in patients who are either in Facilities for bacteriological culture and suscepti­ hospital or who have recently been discharged from bility testing are generally not available at the hospital. The causative organism is derived either peripheral level. Laboratory support in microbiology from the patient's endogenous flora or from the will be limited to microscopy and to some simple flora which are endemic in the hospital. and rapid tests for the detection of antibodies (typhoid, syphilis) or antigens (meningitis, Causative Drugs used as markers Chlamydia). organisms of antimicrobial resistance Most intermediate laboratories should have the facilities to culture, identify and establish the Staphylococcus aureus benzylpenicillin susceptibility of common pathogens such as erythromycin, oxacillin Shigella, Salmonella spp., Vibrio cholerae, gentamicin, (vancomycin? staphylococci, nosocomial Gram-negative bacilli, streptococci, meningococci, gonococci, pneumo­ Coagulase-negative benzylpenicillin cocci and Haemophilus influenzae. Susceptibility staphylococci erythromycin, oxacillin testing should also be routinely performed at least gentamicin, (vancomycin? for rapidly-growing pathogens. For fastidious bacteria, testing may be limited to rapid, inexpen­ Enterococci ampicillin, gentamicin sive methods notably beta-lactamase testing of (vancomycin)2 Haemophilus and gonococci and elementary or disc-test screening, using for instance oxacillin as a Pathogenic Gram-negative ampicillin marker for penicillin resistance in pneumococci. bacilli epidemic or endemic chloramphenicol in hospitals sulfamethoxazole All isolates of Shigella, Salmonella and Vibrio spp. including E. coli, trimethoprim and representative isolates of pneumococci, Klebsiella spp., gentamicin, (fluoroquinolone)2 H. influenzae, meningococci and gonococci should 3 Salmonella, (cefalosporin ) be forwarded to a central
Recommended publications
  • Mediated Peptidoglycan Cross-Linking and B-Lactam Resistance In
    RESEARCH ARTICLE Factors essential for L,D-transpeptidase- mediated peptidoglycan cross-linking and b-lactam resistance in Escherichia coli Jean-Emmanuel Hugonnet1,2,3, Dominique Mengin-Lecreulx4, Alejandro Monton5, Tanneke den Blaauwen5, Etienne Carbonnelle1,2,3, Carole Veckerle´ 1,2,3, Yves, V. Brun6, Michael van Nieuwenhze6, Christiane Bouchier7, Kuyek Tu1,2,3, Louis B Rice8, Michel Arthur1,2,3* 1INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 2Sorbonne Universite´s, UPMC Universite´ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 3Universite´ Paris Descartes, Sorbonne Paris Cite´, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 4Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Universite´ Paris-Sud, Universite´ Paris-Saclay, Gif-sur-Yvette, France; 5Bacterial Cell Biology and Physiology, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, Netherlands; 6Indiana University, Indiana, United States; 7Institut Pasteur, Paris, France; 8Rhode Island Hospital, Brown University, Providence, United States Abstract The target of b-lactam antibiotics is the D,D-transpeptidase activity of penicillin- binding proteins (PBPs) for synthesis of 4fi3 cross-links in the peptidoglycan of bacterial cell walls. Unusual 3fi3 cross-links formed by L,D-transpeptidases were first detected in Escherichia coli more than four decades ago, however no phenotype has previously been associated with their synthesis. Here we show that production of the L,D-transpeptidase YcbB in combination with elevated *For correspondence: michel. synthesis of the (p)ppGpp alarmone by RelA lead to full bypass of the D,D-transpeptidase activity [email protected] of PBPs and to broad-spectrum b-lactam resistance.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Correlation of Phenotypic Tests with the Presence of the Blaz
    b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 8 (2 0 1 7) 159–166 ht tp://www.bjmicrobiol.com.br/ Medical Microbiology Correlation of phenotypic tests with the presence of the blaZ gene for detection of beta-lactamase a,b a a Adriano Martison Ferreira , Katheryne Benini Martins , Vanessa Rocha da Silva , c a,b,∗ Alessandro Lia Mondelli , Maria de Lourdes Ribeiro de Souza da Cunha a Universidade Estadual Paulista (UNESP), Botucatu Biosciences Institute, Department of Microbiology and Immunology, Botucatu, SP, Brazil b Universidade Estadual Paulista (UNESP), Botucatu School of Medicine University Hospital, Department of Tropical Diseases, Botucatu, SP, Brazil c Universidade Estadual Paulista (UNESP), Botucatu School of Medicine University Hospital, Department of Internal Medicine, Botucatu, SP, Brazil a r a t i c l e i n f o b s t r a c t Article history: Staphylococcus aureus and Staphylococcus saprophyticus are the most common and most impor- Received 3 July 2015 tant staphylococcal species associated with urinary tract infections. The objective of the Accepted 20 June 2016 present study was to compare and to evaluate the accuracy of four phenotypic methods Available online 11 November 2016 for the detection of beta-lactamase production in Staphylococcus spp. Seventy-three strains Associate Editor: John Anthony produced a halo with a diameter ≤28 mm (penicillin resistant) and all of them were positive McCulloch for the blaZ gene. Among the 28 susceptible strain (halo ≥29 mm), 23 carried the blaZ gene and five did not.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Moraxella Catarrhalis Uses a Twin-Arginine Translocation System to Secrete the Β-Lactamase BRO-2 Rachel Balder1, Teresa L Shaffer2 and Eric R Lafontaine1*
    Balder et al. BMC Microbiology 2013, 13:140 http://www.biomedcentral.com/1471-2180/13/140 RESEARCH ARTICLE Open Access Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2 Rachel Balder1, Teresa L Shaffer2 and Eric R Lafontaine1* Abstract Background: Moraxella catarrhalis is a human-specific gram-negative bacterium readily isolated from the respiratory tract of healthy individuals. The organism also causes significant health problems, including 15-20% of otitis media cases in children and ~10% of respiratory infections in adults with chronic obstructive pulmonary disease. The lack of an efficacious vaccine, the rapid emergence of antibiotic resistance in clinical isolates, and high carriage rates reported in children are cause for concern. Virtually all Moraxella catarrhalis isolates are resistant to β-lactam antibiotics, which are generally the first antibiotics prescribed to treat otitis media in children. The enzymes responsible for this resistance, BRO-1 and BRO-2, are lipoproteins and the mechanism by which they are secreted to the periplasm of M. catarrhalis cells has not been described. Results: Comparative genomic analyses identified M. catarrhalis gene products resembling the TatA, TatB, and TatC proteins of the well-characterized Twin Arginine Translocation (TAT) secretory apparatus. Mutations in the M. catarrhalis tatA, tatB and tatC genes revealed that the proteins are necessary for optimal growth and resistance to β-lactams. Site-directed mutagenesis was used to replace highly-conserved twin arginine residues in the predicted signal sequence of M. catarrhalis strain O35E BRO-2, which abolished resistance to the β-lactam antibiotic carbanecillin. Conclusions: Moraxella catarrhalis possesses a TAT secretory apparatus, which plays a key role in growth of the organism and is necessary for secretion of BRO-2 into the periplasm where the enzyme can protect the peptidoglycan cell wall from the antimicrobial activity of β-lactam antibiotics.
    [Show full text]
  • Cefalotin Sodium(BANM, Pinnm)
    Cefadroxil/Cefalotin Sodium 219 not appreciably altered. Up to 15% of a dose is bound Keflex; Pondnacef; Sefasin; Sialexin; Sporicef; Sporidex; Toflex; Ulflex; Pharmacopoeias. In Chin., Eur. (see p.vii), Jpn, and US. Zeplex; Turk.: Maksipor; Sef; UAE: Cefrin; UK: Ceporex; Keflex; USA: Ph. Eur. 6.2 (Cefalotin Sodium). A white or almost white pow- to plasma proteins. The plasma half-life is about 1 Biocef†; Cefanex; Keflex; Keftab†; Venez.: Bidocef; Cefaloga†; Keforal; Stricef. der. Freely soluble in water; slightly soluble in dehydrated alco- hour; it increases with reduced renal function. hol. A 10% solution in water has a pH of 4.5 to 7.0. Protect from Multi-ingredient: India: Caceff; Cephadex LB; Mex.: Arlexen B; Cefab- Cefalexin is widely distributed in the body but does not roxil; Cepobrom; Mucocef; Rombox. light. enter the CSF in significant quantities. It crosses the USP 31 (Cephalothin Sodium). A white to off-white, practically placenta and small quantities are found in breast milk. odourless, crystalline powder. Freely soluble in water, in sodium Cefalexin is not metabolised. About 80% or more of a chloride 0.9%, and in glucose solutions; insoluble in most organ- Cefalonium (BAN, pINN) ic solvents. pH of a 25% solution in water is between 4.5 and 7.0. dose is excreted unchanged in the urine in the first 6 41071; Carbamoylcefaloridine; Cefalonio; Céfalonium; Cephalo- Store in airtight containers. hours by glomerular filtration and tubular secretion; nium. (7R)-3-(4-Carbamoyl-1-pyridiniomethyl)-7-[2-(2-thienyl)- Incompatibility and stability. Cefalotin sodium has been re- urinary concentrations greater than 1 mg/mL have acetamido]-3-cephem-4-carboxylate.
    [Show full text]
  • Chemistry Classification Pharmacokinetics Clinical Uses And
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(11):28-58 ISSN : 0975-7384 Review Article CODEN(USA) : JCPRC5 Chemistry, classification, pharmacokinetics, clinical uses and analysis of beta lactam antibiotics: A review Mamdouh S. Masoud a, Alaa E. Ali b* and Nessma M. Nasr c aChemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt bChemistry Department, Faculty of Science, Damanhour University, Damanhour, Egypt cStudents’ Hospital, Alexandria University, Alexandria, Egypt _____________________________________________________________________________________________ ABSTRACT This review attempts to pinpoint the importance of betalactam antibiotics, which encompass penicillins, cephalosporins, cephamycins, carbapenems and monobactams from its chemistry, classification, pharmacokinetics, clinical uses and analysis. β- lactam antibiotics have been used for treatment of bacterial infections. Most antibacterials are chemically semisynthetic modifications of various natural compounds and classified on the basis of chemical /biosynthetic origin into natural, semisynthetic, and synthetic. Also, this classification system is based on biological activity; that antibacterials are divided into two broad groups according to their biological effect on microorganisms, bactericidal agents kill bacteria, and bacteriostatic agents slow down bacterial growth. Keywords: Beta lactam Antibiotics, Classification, Pharmacokinetics, Clinical uses, Analysis. _____________________________________________________________________________________________
    [Show full text]
  • Chromatography
    focus on Chromatography Monolithic Silica Columns for Simple and Fast LC-MS Analysis of Antibiotics in Mammalian Tissue and Body Fluid and in Pharmaceutical Formulations Stephan Altmaier, Merck Millipore, Frankfurter Str. 250, 64293 Darmstadt, Germany This work describes fast and straightforward high performance liquid chromatography methods with UV or mass spectrometry detection for the analysis of antibiotics in mammalian tissue or urine and in pharmaceutical formulations. The monolithic and very robust silica structure of the columns used in this work allows for short sample preparation procedures. All samples were separated on C18 reversed phase columns via gradient elution profi les and directly transferred to UV or MS for the analysis of all components. This setup enabled the identifi cation of antibiotics in samples such as urine or liver within very short analysis times and with a sample preparation step kept as short as possible. Antibiotics are natural products of metabolism of bacteria, fungi or organisms such as Table I: List of antibiotics analysed in this work: Names, corresponding monoisotopic mass, plants and amphibians, generated in order to fi ght an infection or to gain advantage in relevant MS peaks (calculated) and molecular ion formulas. genetic selection. Examples for such natural antibiotics are allicin from garlic, Echinacea plant extract, honey containing antimicrobial enzymes or cinnamon. Antibiotic compound Monoisotopic Relevant MS peak / m/z From a more medical point of view, antibiotics are a class of drug substances blocking mass / g/Mol metabolic processes of microorganisms. As a result, reproduction and viability of these Cephalosporin C 415.1 416.1 microorganisms is prevented.
    [Show full text]
  • MEDLINE Title and Abstract Search Strategy for the Effects of Antibiotic Prophylaxis in Patients with Open Fracture 1
    COPYRIGHT © 2019 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED CHANG ET AL. ANTIBIOTIC PROPHYLAXIS IN THE MANAGEMENT OF OPEN FRACTURES: A SYSTEMATIC SURVEY OF CURRENT PRACTICE AND RECOMMENDATIONS http://dx.doi.org/10.2106/JBJS.RVW.17.00197 Page 1 Appendix MEDLINE Title and Abstract Search Strategy for the Effects of Antibiotic Prophylaxis in Patients with Open Fracture 1. antibiotics.mp. or exp anti-bacterial agents/ 2. antibiotic prophylaxis.mp. or exp antibiotic prophylaxis/ 3. (anti-microb* or anti bact* or antibact*).mp. 4. (antibiotic* or antimicrob*).mp. 5. cephalothin.mp. 6. antibioprophylaxis.mp. 7. cloxacillin.mp. 8. exp amoxicillin/or amoxicillin.mp. 9. exp ampicillin/or ampicillin.mp. 10. clavulanic acid.mp. 11. amoxiclav.mp. 12. augmentin.mp. 13. ticarcillin.mp. 14. exp cephalosporins/or cephalosporin*.mp. 15. (keflex or cefamandole or kefadol or cefazolin* or kefzol or cefixime or suprax).mp. 16. (cefotaxime or claforan or cefoxitin or mefoxin or cefpirome or cefrom or cefpodoxime).mp. 17. (orelox or cefprozil or cefzil or cefradine or velosel or ceftazidim or ortum or kefadim).mp. 18. (ceftriaxone or rocephin or cefuroxime or zinacef or zinnat or cefonicid or aztreonam).mp. 19. (azactam or imipenem or ilastatin or primaxin or meropenem).mp. 20. (tetracycline* or deteclo or demecleocyclin or ledermycin or doxycycline or vibramycin).mp. 21. (minocycline or minocine or oxytetracycline or terramycin or macrolide*).mp. 22. (erythromycin or erymax or erythrocin or erythroped or azithromycin or zithromax).mp. 23. (clarithromycin or klaricid or telithromycin or ketek or trimoxazole or septrin).mp. 24. (trimethoprim or monotrim or trimopan or metronidazole or flagyl or metrolyl).mp.
    [Show full text]
  • Revision of Precautions
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Cefmenoxime hydrochloride (preparations for otic and nasal use), chloramphenicol (solution for topical use, oral dosage form), tetracycline hydrochloride (powders, capsules), polymixin B sulfate (powders), clindamycin hydrochloride, clindamycin phosphate (injections), benzylpenicillin potassium, benzylpenicillin benzathine hydrate, lincomycin hydrochloride hydrate, aztreonam, amoxicillin hydrate, ampicillin hydrate, ampicillin sodium, potassium clavulanate/amoxicillin hydrate, dibekacin sulfate (injections), sultamicillin tosilate hydrate, cefaclor, cefazolin sodium, cefazolin sodium hydrate, cephalexin (oral dosage form with indications for otitis media), cefalotin sodium, cefixime hydrate, cefepime dihydrochloride hydrate, cefozopran hydrochloride, cefotiam hydrochloride (intravenous injections), cefcapene pivoxil hydrochloride hydrate, cefditoren pivoxil, cefdinir, ceftazidime hydrate, cefteram pivoxil, ceftriaxone sodium hydrate, cefpodoxime proxetil, cefroxadine hydrate, cefuroxime axetil, tebipenem pivoxil, doripenem hydrate, bacampicillin hydrochloride, panipenem/betamipron, faropenem sodium hydrate, flomoxef sodium, fosfomycin calcium hydrate, meropenem hydrate, chloramphenicol sodium succinate,
    [Show full text]
  • Β-Lactamase Production and Antibiotic Susceptibility Pattern of Moraxella
    Shi et al. BMC Microbiology (2018) 18:77 https://doi.org/10.1186/s12866-018-1217-5 RESEARCH ARTICLE Open Access β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China Wei Shi1†, Denian Wen2†, Changhui Chen3†, Lin Yuan1, Wei Gao1, Ping Tang2, Xiaoping Cheng3 and Kaihu Yao1* Abstract Background: Moraxella catarrhalis (M. catarrhalis) is an important bacterial pathogen. However, its antibiotic susceptibility patterns in different areas are difficult to compare because of the use of different methods and judgement criteria. This study aimed to determine antimicrobial susceptibility and β-lactamase activity characteristics of M. catarrhalis isolates collected from two county hospitals in China, and to express the results with reference to three commonly used judgement criteria. Results: Nasopharyngeal swabs were obtained from child inpatients with respiratory tract infections at the People’s Hospital of Zhongjiang County and Youyang County from January to December 2015. M. catarrhalis strains were isolated and identified from the swabs, and susceptibility against 11 antimicrobials was determined using the E-test method or disc diffusion. Test results were interpreted with reference to the standards of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Clinical and Laboratory Standards Institute (CLSI), and the British Society for Antimicrobial Chemotherapy (BSAC). Detection of β-lactamase activity was determined by the chromogenic cephalosporin nitrocefin. M. catarrhalis yield rates were 7.12 and 9.58% (Zhongjiang County, 77/1082 cases; Youyang County, 101/1054 cases, respectively). All isolates were susceptible to amoxicillin–clavulanic acid. The susceptibility rate to meropenem was 100% according to EUCAST; no breakpoints were listed in CLSI or BSAC.
    [Show full text]